Sort
89,613 grants matching “depression”
Office of the Scientific Director
$6,374,025Richard Nakamura · National Institute Of Mental Health · ZIA · FY2010 · MH
Einstein Aging Study
$6,355,589Carol A Derby · Albert Einstein College Of Medicine · P01 · FY2024 · AG
Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder
$6,354,906Andrew Walker · Emergent Product Development Gaithersbur · UG3 · FY2019 · DA
NIAAA Repository/Screening Database Management and Research
$6,351,050Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2025 · AA
MGT SVCS/CONTRACT & PROCUREMENT SUP
$6,347,314X X · Massachusetts General Hospital · N01 · FY2013 · DA
NIMH Center for Collaborative Genetic Studies
$6,307,200Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · U24 · FY2008 · MH
Development of an implantable closed-loop system for delivery of naloxone for the prevention of opioid-related overdose deaths
$6,275,050Robert W Gereau · Washington University · UH3 · FY2021 · DA
Clinical Core
$6,233,431Ziad Nahas · University Of Minnesota · U54 · FY2023 · AT
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy
$6,167,288Shalendar Bhasin · Brigham And Women'S Hospital · U01 · FY2015 · AG
Environmental influences on Child Health Outcomes in the Northern Plains PASS-ECHO Cohort
$6,134,134Amy J Elliott · Avera Mckennan · UG3 · FY2024 · OD
Non-invasive Neuromodulation Unit (NNU)
$6,121,276Sarah Lisanby · National Institute Of Mental Health · ZIA · FY2023 · MH
NIAAA Repository/Screening Database Management and Research
$6,107,809Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2024 · AA
Process Development, Manufacturing, and Preclinical Evaluation of a Monoclonal Antibody for Fentanyl Overdose
$6,107,502Paul T Bremer · Cessation Therapeutics, Llc · U01 · FY2020 · DA
Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder
$6,075,000Katherine Beebe Devarney · Titan Pharmaceuticals, Inc. · UG3 · FY2019 · DA
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
$6,072,987John Alam · Eip Pharma, Inc. · R01 · FY2025 · AG
Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)
$6,065,228Adam L Boxer · University Of California, San Francisco · R56 · FY2022 · AG
NIAAA Repository/Screening Database Management and Research
$6,000,557Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2023 · AA
Evaluation of the Safety and Efficacy of a New Oral Small Molecule GABA-B Receptor Positive Allosteric Modulator (PAM) as an Add-on Maintenance Therapy for Opioid Use Disorder (OUD)
$6,000,000Jay Erdman · Astellas Pharma Global Development, Inc. · UG3 · FY2020 · DA
Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial
$5,944,011Dalane W Kitzman · Wake Forest University Health Sciences · R01 · FY2022 · AG
Office of the Scientific Director
$5,875,763Susan Amara · National Institute Of Mental Health · ZIA · FY2016 · MH
ADEPT: ADAPTIVE TRIAL FOR THE TREATMENT OF DEPRESSIVE SYMPTOMS ASSOCIATED WITH CONCUSSION USING REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION PROTOCOLS
$5,849,680The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. · · FY2025 · Defense Health Agency
Integrative genetics of behavior with high throughput technologies
$5,808,197David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2024 · AA
NIAAA Repository/Screening Database Management and Research
$5,788,835Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2022 · AA
ALZHEIMERS DISEASE COOPERATIVE STUDY
$5,761,712University Of California San Diego · U01 · FY2000 · AG
fMRI Studies of Pediatric Mood and Anxiety Disorders
$5,705,745Daniel Pine · National Institute Of Mental Health · ZIA · FY2025 · MH